Table 1 Patients characteristics at initial treatment and at recurrence
From: Reassessment of intensive surveillance practices adopted for endometrial cancer survivors
Characteristics | Patients | n = 88 |
|---|---|---|
Initial cancer | Â | Â |
 Age | 32–82 (63) |  |
FIGO stage | Â | Â |
 I | 30 | (34.1) |
 II | 4 | (4.5) |
 III | 38 | (43.2) |
 IV | 16 | (18.2) |
Histology | Â | Â |
 Eendometrioid G1-G2 | 52 | (59.1) |
 Endometrioid G3 | 15 | (17.0) |
 Serous | 5 | (5.7) |
 Others | 16 | (18.2) |
Initial treatment | Â | Â |
 Operation |  |  |
  ATH + BSO | 19 | (21.6) |
  ATH + BSO + PLA biopsy | 12 | (13.6) |
  ATH + BSO + PLA | 31 | (35.2) |
  ATH + BSO + PLA + PAN | 22 | (25.0) |
  NAC + ATH | 4 | (4.5) |
 Chemotherapy |  |  |
  No | 28 | (31.8) |
  Yes | 60 | (68.2) |
At recurrence | Â | Â |
 Follow up interval |  |  |
  1 month | 44 | (50.0) |
  2 months | 20 | (22.7) |
  3 > months | 24 | (27.3) |
 Recurrence site |  |  |
  Local | 17 | (19.3) |
  Pelvic and para-aortic LN | 13 | (14.8) |
  Peritoneal dissemination | 13 | (14.8) |
  Distant metastasis | 45 | (51.1) |
 Method of diagnosis |  |  |
  Symptom | 22 | (25.0) |
  Tumor marker | 16 | (18.2) |
  Imaging analysis | 37 | (42.0) |
  Outpatient exam | 13 | (14.8) |